An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor.

ABSTRACT:

Background

Molecular analysis has revealed four subtypes of pancreatic ductal adenocarcinoma (PDAC). One subtype identified for the presence of DNA damage repair deficiency can be targeted therapeutically with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib. We performed a single institution retrospective analysis of treatment response in patients with PDAC treated with olaparib who have DNA damage repair deficiency mutations.

Subjects, materials, and methods

Patients with germline or somatic mutations involving the DNA repair pathway were identified and treated with olaparib. The primary objective was to examine the objective response rate (ORR). The secondary objectives were assessing tolerability, overall survival, and change in cancer antigen 19-9. Quantitativ

SUBMITTER: Borazanci E 

PROVIDER: S-EPMC6964119 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature